Relationship between donepezil and fracture risk in patients with dementia with Lewy bodies.
dementia with Lewy bodies
donepezil
fracture
Journal
Geriatrics & gerontology international
ISSN: 1447-0594
Titre abrégé: Geriatr Gerontol Int
Pays: Japan
ID NLM: 101135738
Informations de publication
Date de publication:
26 Jun 2024
26 Jun 2024
Historique:
revised:
07
06
2024
received:
13
05
2024
accepted:
13
06
2024
medline:
26
6
2024
pubmed:
26
6
2024
entrez:
26
6
2024
Statut:
aheadofprint
Résumé
Patients with dementia with Lewy bodies (DLB) are at a high risk for falls and fractures. Although cholinesterase inhibitors reportedly are effective in suppressing the progression of cognitive symptoms in DLB patients, their effects on fracture risk remain unclarified. This study aimed to evaluate the association between donepezil use and hip fracture risk in older patients with DLB. Using the Japanese insurance claim database, we collected the data of patients aged ≥65 years with DLB from April 2012 to March 2019. After propensity score matching, we compared the fracture rate over 3 years between DLB patients receiving donepezil and those not receiving antidementia drugs. Altogether, 24 022 239 individuals aged ≥65 years were newly registered from April 2012 to March 2016 and had verifiable information from 6 months before to 3 years after the registration. We identified 6634 pure-DLB patients and analyzed the data of 1182 propensity score-matched pairs. The characteristics, including age, sex, fracture history, osteoporosis, and bone mineral density test rate, of the two groups were well balanced by propensity score matching. The incidence rate of hip fracture was significantly lower in DLB patients receiving donepezil than in those not receiving antidementia drugs (0.60 vs. 1.44/100 person-years, P < 0.001), whereas that of vertebral fractures was the same. Donepezil administration in Japanese people aged ≥65 years with DLB was significantly associated with a decreased risk of hip fracture. Donepezil may provide new benefits to DLB patients. Geriatr Gerontol Int 2024; ••: ••-••.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Geriatrics & Gerontology International published by John Wiley & Sons Australia, Ltd on behalf of Japan Geriatrics Society.
Références
Hogan DB, Fiest KM, Roberts JI et al. The prevalence and incidence of dementia with Lewy bodies: a systematic review. Can J Neurol Sci 2016; 43: S83–S95.
Sanford AM. Lewy body dementia. Clin Geriatr Med 2018; 34: 603–615.
McKeith IG, Boeve BF, Dickson DW et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB consortium. Neurology 2017; 89: 88–100.
Allan LM, Ballard CG, Rowan EN, Kenny RA. Incidence and prediction of falls in dementia: a prospective study in older people. PLoS One 2009; 4: e5521.
Imamura T, Hirono N, Hashimoto M et al. Fall‐related injuries in dementia with Lewy bodies (DLB) and Alzheimer's disease. Eur J Neurol 2000; 7: 77–79.
Enemark M, Midttun M, Winge K. Evaluating outcomes for older patients with Parkinson's disease or dementia with Lewy bodies who have been hospitalised for hip fracture surgery: potential impact of drug administration. Drugs Aging 2017; 34: 387–392.
Montero‐Odasso M, Speechley M. Falls in cognitively impaired older adults: implications for risk assessment and prevention. J Am Geriatr Soc 2018; 66: 367–375.
Hershey LA, Coleman‐Jackson R. Pharmacological management of dementia with Lewy bodies. Drugs Aging 2019; 36: 309–319.
Aarsland D, Ballard C, Walker Z et al. Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double‐blind, placebo‐controlled, multicentre trial. Lancet Neurol 2009; 8: 613–618.
Emre M, Tsolaki M, Bonuccelli U et al. Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double‐blind, placebo‐controlled trial. Lancet Neurol 2010; 9: 969–977.
MacDonald S, Shah AS, Tousi B. Current therapies and drug development pipeline in Lewy body dementia: an update. Drugs Aging 2022; 39: 505–522.
Tsunoda R, Mitsutake N, Ishikawa T et al. Monthly trends and seasonality of hemodialysis treatment and outcomes of newly initiated patients from the national database (NDB) of Japan. Clin Exp Nephrol 2022; 26: 669–677.
Hosoi T, Yakabe M, Matsumoto S et al. Relationship between antidementia medication and fracture prevention in patients with Alzheimer's dementia using a nationwide health insurance claims database. Sci Rep 2023; 13: 6893.
Guidelines on the Prevention and Treatment of Osteoporosis 2015. The committee for development of the guidelines on the prevention and treatment of osteoporosis. (in Japanese). Japan Osteoporosis Society (online), Available at: http://www.josteo.com/ja/guideline/doc/15_1.pdf. Accessed May 9, 2024.
Normand ST, Landrum MB, Guadagnoli E et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol 2001; 54: 387–398.
Agresti A, Caffo B. Simple and effective confidence intervals for proportions and differences of proportions result from adding two successes and two failures. Am Stat 2000; 54: 280–288.
Schousboe JT. Epidemiology of vertebral fractures. J Clin Densitom 2016; 19: 8–22.
Ogunwale AN, Colon‐Emeric CS, Sloane R, Adler RA, Lyles KW, Lee RH. Acetylcholinesterase inhibitors are associated with reduced fracture risk among older veterans with dementia. J Bone Miner Res 2020; 35: 440–445.
Tamimi I, Ojea T, Sanchez‐Siles JM et al. Acetylcholinesterase inhibitors and the risk of hip fracture in Alzheimer's disease patients: a case‐control study. J Bone Miner Res 2012; 27: 1518–1527.
Tamimi I, Nicolau B, Eimar H et al. Acetylcholinesterase inhibitors and the risk of osteoporotic fractures: nested case‐control study. Osteoporos Int 2018; 29: 849–857.
Chung KA, Lobb BM, Nutt JG, Horak FB. Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease. Neurology 2010; 75: 1263–1269.
Henderson EJ, Lord SR, Brodie MA et al. Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double‐blind, placebo‐controlled, phase 2 trial. Lancet Neurol 2016; 15: 249–258.
Kim DH, Brown RT, Ding EL, Kiel DP, Berry SD. Dementia medications and risk of falls, syncope, and related adverse events: meta‐analysis of randomized controlled trials. J Am Geriatr Soc 2011; 59: 1019–1031.
Ahuja M, Siddhpuria S, Karimi A et al. Cholinesterase inhibitors and falls, syncope and injuries in patients with cognitive impairment: a systematic review and meta‐analysis. Age Ageing 2023; 52: afad205.
Joza S, Camicioli R, Ba F. Falls in synucleinopathies. Can J Neurol Sci 2020; 47: 30–43.
Buckley JS, Salpeter SR. A risk‐benefit assessment of dementia medications: systematic review of the evidence. Drugs Aging 2015; 32: 453–467.
Sato T, Enoki Y, Sakamoto Y et al. Donepezil prevents RANK‐induced bone loss via inhibition of osteoclast differentiation by downregulating acetylcholinesterase. Heliyon 2015; 1: e00013.
Gill SS, Anderson GM, Fischer HD et al. Syncope and its consequences in patients with dementia receiving cholinesterase inhibitors: a population‐based cohort study. Arch Intern Med 2009; 169: 867–873.
Matsumoto S, Tamiya H, Yamana H et al. Association between the type of hypnotic drug and in‐hospital fractures in older patients with neurocognitive disorders: a case‐control study using a nationwide database. Geriatr Gerontol Int 2023; 23: 500–505.
Kanis JA, Harvey NC, Johansson H, Odén A, Leslie WD, McCloskey EV. FRAX and fracture prediction without bone mineral density. Climacteric 2015; 18: 2–9.
Haentjens P, Magaziner J, Colón‐Emeric CS et al. Meta‐analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 2010; 152: 380–390.